Peripheral T-Cell Lymphoma: New Advances for a Difficult Disease

Tuesday, March 22, 2016

5:30pm Registration6:00pm Dinner6:30pm Presentation

Lidia’s The Loft1400 Smallman StPttisburgh, PA

FACULTY

This activity is provided byMedical Learning Institute, Inc.

This activity is supported by educationalgrants from Spectrum Pharmaceuticals, Incand Celgene Corporation.

Barbara Rogers CRNP, MN, AOCN®, ANP-BCAdult Hematology-Oncology Nurse PractitionerFox Chase Cancer CenterPhiladelphia, PA

Web Flyer.PTCL.ONS chap.PA.Mar22_Layout 4 1/13/2016 12:34 PM Page 1

REGISTERED NURSE DESIGNATIONMedical Learning Institute, Inc.Provider approved by the California Board ofRegistered Nursing, Provider Number 15106 for1.0 contact hour.

NURSE PRACTITIONER CREDIT DESIGNATIONThis program is approved for 1.0 contacthour(s) of continuing education by theAmerican Association of Nurse Practitioners.Program ID 1508341. This program wasplanned in accordance with AANP CE Standards and Policies.

INSTRUCTIONS FOR CREDIT

There is no fee for this activity.To receive credit for this CE activity, please take afew minutes to complete the pre-activity assessmentand evaluation form and return it to the on-sitecoordinator. Your confirmation of reportedparticipation will be e-mailed to you within 4 weeks.If you choose to complete this evaluation form off-site, return it by mail or fax to:

Medical Learning Institute, Inc.203 Main Street, Suite 249

Flemington, NJ 08822609.333.1694 (fax)

For questions regarding the accreditation of thisactivity, please contact Medical Learning Institute, Inc.at 609.333.1693 or mvu@mlicme.org.

LEARNING OBJECTIVES

Upon completion of this activity, the participantwill be able to:

Describe the clinical manifestations of PTCL•

Discuss the rationale for the use of approved•and emerging treatment options based oncurrent NCCN guidelinesIdentify adverse effects associated with•therapies used in the treatment of PTCL

Apply nursing interventions to manage the•side effects of PTCL treatments andexpectations of patients

PROGRAM DESCRIPTIONAlthough management of PTCL has generallyfollowed the treatment paradigm of large B-celllymphoma, outcomes have been poorer. PTCLis rare and the most concerning aspects ofmanagement for nurses are:

Diagnosis•Symptom and side effect management•Treatment/new data•Patient education and management•

This curriculum is designed to educate oncologynurses on preventing, identifying, and treatingserious side effects while managing the patientwith PTCL. The curriculum will enable thehealthcare team to adjust managementstrategies for that patient, to avoid or minimizea serious complication.

TARGET AUDIENCE

This educational activity will be directed towardoncology nurses and nurse practitioners involvedin the management of patients with PTCL.

PURPOSE STATEMENT

The purpose of this activity is to enhance thecompetence of nurses and nurse practitionersconcerning the management of patients withPeripheral T-Cell Lymphoma (PTCL).

5 minutes Introduction to Program / Overview Pre-test

25 minutes Overview of PTCL to include current NCCN guidelines

Epidemiology Symptoms Current ParadigmNew Directions in Management:Single Agents and Combinations

10 minutes Case 1 –Anticipating and Identifying Adverse Events

Managing patient expectations Side effects vs. disease progression

10 minutes Case 2 –Managing Adverse Events Most common adverse events Nursing interventions

10 minutes Conclusions and Q&A

PROGRAM AGENDA

REGISTRATION INFORMATION

You can register for this activity by logging onto:

http://ptclpittsburghons.eventbrite.com

AMERICANS WITH DISABILITIES ACT- Event staff will be glad to assist you with anyspecial needs (ie, physical, dietary, etc). Please contact Medical Learning Institute,Inc. prior to the live event at 609.333.1693x103.

Web Flyer.PTCL.ONS chap.PA.Mar22_Layout 4 1/13/2016 12:34 PM Page 2